Declining Efficacy of Artemisinin Combination Therapy Against P. Falciparum Malaria on the Thai-Myanmar Border (2003-2013): The Role of Parasite Genetic Factors

Clinical Infectious Diseases

Volumn 63, Issue 6, 2016, Pages 784-791

  Phyo, Aung Pyae ^a,b   Ashley, Elizabeth A ^a,b,c   Anderson, Tim J C ^d   Bozdech, Zbynek ^e   Carrara, Verena I ^a,c   Sriprawat, Kanlaya ^a   Nair, Shalini ^d   White, Marina McDew ^d   Dziekan, Jerzy ^e   Ling, Clare ^a,b,c   Proux, Stephane ^a   Konghahong, Kamonchanok ^a   Jeeyapant, Atthanee ^c   Woodrow, Charles J ^b,c   Imwong, Mallika ^c   McGready, Rose ^a,b   Lwin, Khin Maung ^a,c   Day, Nicholas P J ^b,c   White, Nicholas J ^b,c   Nosten, Francois ^a,b  

^a SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c MAHIDOL UNIVERSITY   (Thailand)

^d SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^e NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

artemisinin resistance; K13 mutation; mefloquine artesunate; Pfmdr1; Plasmodium falciparum malaria

Indexed keywords

ARTESUNATE; MEFLOQUINE; MOLECULAR MARKER; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

ADOLESCENT; ANTIMALARIAL DRUG RESISTANCE; ANTIPROTOZOAL THERAPY; ARTICLE; COMBINATION DRUG THERAPY; DRUG EFFICACY; FEMALE; GENE MUTATION; HUMAN; KELCH 13 GENE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MICROBIAL GENE; MYANMAR; PARASITE CLEARANCE; PFMDR1 GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; THAILAND; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; PARASITOLOGY; PATHOGENICITY; PLASMODIUM FALCIPARUM;

ANTIMALARIALS; ARTEMISININS; DRUG RESISTANCE; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; MEFLOQUINE; MYANMAR; PLASMODIUM FALCIPARUM; PROSPECTIVE STUDIES; THAILAND;

EID: 84995428289     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw388     Document Type: Article

References (40)

1. Nosten F, Imvithaya S, Vincenti M, et al. Malaria on the Thai-Burmese border: treatment of 5192 patients with mefloquine-sulfadoxine-pyrimethamine. Bull World Health Organ 1987; 65:891-6.
2. Nosten F, Luxemburger C, ter Kuile FO, et al. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis 1994; 170:971-7.
3. Nosten F, ter Kuile F, Chongsuphajaisiddhi T, et al. Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet 1991; 337:1140-3.
4. Price RN, Uhlemann AC, Brockman A, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004; 364:438-47.
5. ter Kuile FO, Nosten F, Thieren M, et al. High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. J Infect Dis 1992; 166:1393-400.
6. Price RN, Nosten F, Luxemburger C, et al. Effects of artemisinin derivatives on malaria transmissibility. Lancet 1996; 347:1654-8.
7. Nosten F, van Vugt M, Price R, et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 2000; 356:297-302.
8. Carrara VI, Lwin KM, Phyo AP, et al. Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai-Myanmar border, 1999-2011: an observational study. PLoS Med 2013; 10:e1001398.
9. Nkhoma SC, Nair S, Al-Saai S, et al. Population genetic correlates of declining transmission in a human pathogen. Mol Ecol 2013; 22:273-85.
10. Noedl H, Se Y, Sriwichai S, et al. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis 2010; 51:e82-9.
11. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455-67.
12. Phyo AP, Nkhoma S, Stepniewska K, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012; 379:1960-6.
13. Cheeseman IH, Miller BA, Nair S, et al. A major genome region underlying artemisinin resistance in malaria. Science 2012; 336:79-82.
14. Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisininresistant Plasmodium falciparum malaria. Nature 2014; 505:50-5.
15. Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2014; 371:411-23.
16. Ferreira PE, Culleton R, Gil JP, Meshnick SR. Artemisinin resistance in Plasmodium falciparum: what is it really? Trends Parasitol 2013; 29:318-20.
17. Hastings IM, Kay K, Hodel EM. How robust are malaria parasite clearance rates as indicators of drug effectiveness and resistance? Antimicrob Agents Chemother 2015; 59:6428-36.
18. Krishna S, Kremsner PG. Antidogmatic approaches to artemisinin resistance: reappraisal as treatment failure with artemisinin combination therapy. Trends Parasitol 2013; 29:313-7.
19. Spring MD, Lin JT, Manning JE, et al. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis 2015; 15:683-91.
20. Miotto O, Amato R, Ashley EA, et al. Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nat Genet 2015; 47:226-34.
21. Amaratunga C, Lim P, Suon S, et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis 2016; 16:357-65.
22. Carrara VI, Zwang J, Ashley EA, et al. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One 2009; 4:e4551.
23. Luxemburger C, Thwai KL, White NJ, et al. The epidemiology of malaria in a Karen population on the western border of Thailand. Trans R Soc Trop Med Hyg 1996; 90:105-11.
24. World Health Organization. Guidelines for the treatment of malaria. 2nd ed. Geneva: World Health Organization, 2010.
25. Ashley EA, Lwin KM, McGready R, et al. An open label randomized comparison of mefloquine-artesunate as separate tablets vs. a new co-formulated combination for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. Trop Med Int Health 2006; 11:1653-60.
26. Brockman A, Paul RE, erson TJ, et al. Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. Am J Trop Med Hyg 1999; 60:14-21.
27. erson TJ, Nair S, Qin H, et al. Are transporter genes other than the chloroquine resistance locus (pfcrt) and multidrug resistance gene (pfmdr) associated with antimalarial drug resistance? Antimicrob Agents Chemother 2005; 49:2180-8.
28. Nair S, Nash D, Sudimack D, et al. Recurrent gene amplification and soft selective sweeps during evolution of multidrug resistance in malaria parasites. Mol Biol Evol 2007; 24:562-73.
29. Lim P, Alker AP, Khim N, et al. Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar J 2009; 8:11.
30. Muhamad P, Chaijaroenkul W, Phompradit P, Rueangweerayut R, Tippawangkosol P, Na-Bangchang K. Polymorphic patterns of pfcrt and pfmdr1 in Plasmodium falciparum isolates along the Thai-Myanmar border. Asian Pac J Trop Biomed 2013; 3:931-5.
31. Preechapornkul P, Imwong M, Chotivanich K, et al. Plasmodium falciparum pfmdr1 amplification, mefloquine resistance, parasite fitness. Antimicrob Agents Chemother 2009; 53:1509-15.
32. Rueangweerayut R, Phyo AP, Uthaisin C, et al. Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. N Engl J Med 2012; 366:1298-309.
33. Price RN, Uhlemann AC, van Vugt M, et al. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis 2006; 42:1570-7.
34. Venkatesan M, Gadalla NB, Stepniewska K, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg 2014; 91:833-43.
35. Triglia T, Foote SJ, Kemp DJ, Cowman AF. Amplification of the multidrug resistance gene pfmdr1 in Plasmodium falciparum has arisen as multiple independent events. Mol Cell Biol 1991; 11:5244-50.
36. Tun KM, Imwong M, Lwin KM, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis 2015; 15:415-21.
37. Huang F, Takala-Harrison S, Jacob CG, et al. A Single mutation in K13 predominates in southern China and is associated with delayed clearance of Plasmodium falciparum following artemisinin treatment. J Infect Dis 2015; 212:1629-35.
38. Putaporntip C, Kuamsab N, Kosuwin R, et al. Natural selection of K13 mutants of Plasmodium falciparum in response to artemisinin combination therapies in Thailand. Clin Microbiol Infect 2016; 22:285e1-8.
39. Chaorattanakawee S, Saunders DL, Sea D, et al. Ex vivo drug susceptibility testing and molecular profiling of clinical Plasmodium falciparum isolates from Cambodia from 2008 to 2013 suggest emerging piperaquine resistance. Antimicrob Agents Chemother 2015; 59:4631-43.
40. Leang R, Taylor WR, Bouth DM, et al. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in Western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother 2015; 59:4719-26.